Martine Paquette

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6010893/publications.pdf

Version: 2024-02-01

706676 651938 28 662 14 25 citations g-index h-index papers 28 28 28 737 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Dysbetalipoproteinemia: Differentiating Multifactorial Remnant Cholesterol Disease From Genetic ApoE Deficiency. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 538-548.	1.8	11
2	Both low-fat and low-carbohydrate diets reduce triglyceride concentration in subjects with multifactorial chylomicronemia syndrome: a randomized crossover study. Nutrition Research, 2022, 101, 43-52.	1.3	6
3	The Evolving Story of Multifactorial Chylomicronemia Syndrome. Frontiers in Cardiovascular Medicine, 2022, 9, 886266.	1.1	4
4	Prevalence, severity and management of hypertriglyceridemia-associated pancreatitis; A 7-year retrospective cohort study at Canadian quaternary care hospitals. Journal of Clinical Lipidology, 2022, 16, 455-462.	0.6	5
5	Montreal-FH-SCORE Predicts Coronary Artery Calcium Score in Patients With Familial Hypercholesterolemia. CJC Open, 2021, 3, 41-47.	0.7	5
6	ANKS1A genotype predicts cardiovascular events in patients with familial hypercholesterolemia. Journal of Clinical Lipidology, 2021, 15, 602-607.	0.6	2
7	Rare Variants in Triglycerides-Related Genes Increase Pancreatitis Risk in Multifactorial Chylomicronemia Syndrome. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3473-e3482.	1.8	17
8	Paternal inheritance predicts earlier cardiovascular event onset in patients with familial hypercholesterolemia. Atherosclerosis, 2021, 329, 9-13.	0.4	9
9	Familial Hypercholesterolemia-Risk-Score: A New Score Predicting Cardiovascular Events and Cardiovascular Mortality in Familial Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 2632-2640.	1.1	42
10	Hemoglobin concentration, hematocrit and red blood cell count predict major adverse cardiovascular events in patients with familial hypercholesterolemia. Atherosclerosis, 2021, 335, 41-46.	0.4	9
11	Response by Paquette and Baass to Letter Regarding Article, "Familial Hypercholesterolemia-Risk-Score: A New Score Predicting Cardiovascular Events and Cardiovascular Mortality in Familial Hypercholesterolemia― Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, e526-e527.	1.1	0
12	Triglycerides, hypertension, and smoking predict cardiovascular disease in dysbetalipoproteinemia. Journal of Clinical Lipidology, 2020, 14, 46-52.	0.6	7
13	Familial chylomicronemia syndrome: an underâ€recognized cause of severe hypertriglyceridaemia. Journal of Internal Medicine, 2020, 287, 340-348.	2.7	61
14	The ZPR1 genotype predicts myocardial infarction in patients with familial hypercholesterolemia. Journal of Clinical Lipidology, 2020, 14, 660-666.	0.6	4
15	Polygenic Contribution to Low-Density Lipoprotein Cholesterol Levels and Cardiovascular Risk in Monogenic Familial Hypercholesterolemia. Circulation Genomic and Precision Medicine, 2020, 13, 515-523.	1.6	36
16	A simplified diagnosis algorithm for dysbetalipoproteinemia. Journal of Clinical Lipidology, 2020, 14, 431-437.	0.6	37
17	Chylomicronemia: Differences between familial chylomicronemia syndrome and multifactorial chylomicronemia. Atherosclerosis, 2019, 283, 137-142.	0.4	67
18	LPA genotype is associated with premature cardiovascular disease in familial hypercholesterolemia. Journal of Clinical Lipidology, 2019, 13, 627-633.e1.	0.6	15

#	Article	IF	CITATION
19	Diabetes is associated with an increased risk of cardiovascular disease in patients with familial hypercholesterolemia. Journal of Clinical Lipidology, 2019, 13, 123-128.	0.6	24
20	A novel mutation in GPIHBP1 causes familial chylomicronemia syndrome. Journal of Clinical Lipidology, 2018, 12, 506-510.	0.6	10
21	Familial hypercholesterolemia: experience from the French-Canadian population. Current Opinion in Lipidology, 2018, 29, 59-64.	1.2	25
22	Predicting cardiovascular disease in familial hypercholesterolemia. Current Opinion in Lipidology, 2018, 29, 299-306.	1.2	31
23	PCSK9 inhibitors in familial hypercholesterolemia:ÂWhat is the evidence?. Journal of Clinical Lipidology, 2018, 12, 1106-1108.	0.6	5
24	The 9p21.3 locus and cardiovascular risk in familial hypercholesterolemia. Journal of Clinical Lipidology, 2017, 11, 406-412.	0.6	17
25	Polygenic risk score predicts prevalence of cardiovascular disease in patients with familial hypercholesterolemia. Journal of Clinical Lipidology, 2017, 11, 725-732.e5.	0.6	90
26	Scavenger Receptor LOX1 Genotype Predicts Coronary Artery Disease in Patients With Familial Hypercholesterolemia. Canadian Journal of Cardiology, 2017, 33, 1312-1318.	0.8	18
27	Cardiovascular disease in familial hypercholesterolemia: Validation and refinement of the Montreal-FH-SCORE. Journal of Clinical Lipidology, 2017, 11, 1161-1167.e3.	0.6	42
28	The Montreal-FH-SCORE: A new score to predict cardiovascular events in familial hypercholesterolemia. Journal of Clinical Lipidology, 2017, 11, 80-86.	0.6	63